title: [Head and neck sarcoma].
abstract: We reviewed patients with primary soft tissue and bone sarcomas treated in our department. Malignant tumors arising in somatic, connective, soft tissues, especially those of the head and neck, are uncommon and few reports have been published. Between 1980 and 1995 15 patients with head and neck sarcoma were seen. The major sites involved included: paranasal sinuses and orbits (2 patients), neck (4) and 1 each in the forehead, temporal region, mandible, parapharyngeal space, tongue, hypopharynx, larynx, cervico-mediastinal region and nasal cavity. Follow-up ranged from 1-16 years. The youngest patient was a 12-year-old male. Rhabdomyosarcoma, one of the most common mesenchymal tumors found in the head and neck, especially in children, was excluded from our study because of its different clinical behavior and its chemosensitivity, unlike other sarcomas. Most of our patients were treated with wide-field resection; 12 received postoperative radiation, and 3 combined surgery and chemotherapy. Wide excision with negative margins is considered an important, positive, prognostic factor, as the extent and adequacy of excision largely determines survival and the incidence of local recurrence. All our patients underwent initial, wide, local excision of the lesion. Our observations strongly suggest that wide resection is the most effective means of therapy for sarcoma of the head and neck. Radical neck dissection was not only performed for manifest regional neck metastases, but was also used for completing the enlarged, wide-excisions of liposarcomas. The worst survival was in patients with osteosarcoma, angiosarcoma and fibrosarcoma, with an absolute 5-year survival of 60% (9/15).
authors.affiliation: ENT and Head and Neck Surgery Dept., Hasharon Hospital, Golda Medical Center, Petah Tikva.
authors.forename: Y
authors.initials: Y
authors.lastname: Zohar
authors.forename: M
authors.initials: M
authors.lastname: Wulikh
authors.forename: H
authors.initials: H
authors.lastname: Aminov
authors.forename: R
authors.initials: R
authors.lastname: Sadov
authors.forename: R
authors.initials: R
authors.lastname: Gal
authors.forename: A
authors.initials: A
authors.lastname: Schwartz
authors.forename: P
authors.initials: P
authors.lastname: Herskovitz
authors.forename: M
authors.initials: M
authors.lastname: Kots
authors.forename: B
authors.initials: B
authors.lastname: Klein
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D012516:Osteosarcoma / Q000628:therapy; D011859:Radiography; D012189:Retrospective Studies; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000628:therapy; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents